COMP <GO>
COLL vs LLY // 10Y YIELD & FRED MACRO BETA
Collegium Pharmaceutical Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: COLL 3
— LLY 9
■ METRIC PARITY
LAST: $24.03 (+3.44%) • MKT CAP: $782.3M
macro-sensitivity
—
LAST: $1,373.70 (+6.63%) • MKT CAP: $1.29T
macro-sensitivity
0.51
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (COLL VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | COLL | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 59.30% | 83.64% | -24.34 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 85.00% | 32.36% | +52.64 | COLL | /roic <GO> |
| EV/EBITDA & P/E Valuation | 3.0x | 36.4x | -33.42 | COLL | /valuation <GO> |
| Free Cash Flow Yield | — | 2.30% | — | TIE | /fcf-yield <GO> |
| Operating Margin | 23.00% | 40.21% | -17.21 | LLY | /operating-margins <GO> |
| Net Profit Margin | 8.10% | 31.90% | -23.80 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 23.60% | 45.51% | -21.91 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.27 | 9.29 | -8.02 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 9/9 | -2.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.9 | 66.6 | -9.70 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | — | 0.51 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 10.4x | 26.3x | -15.85 | COLL | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $782.3M | $1.29T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | COLL REV | LLY REV | COLL GROSS % | LLY GROSS % | COLL FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $780.6M | $65.18B | 59.3% | 83.0% | $327.6M | $16.81B |
| FY 2024 | $631.4M | $45.04B | 59.8% | 81.3% | $203.3M | $8.82B |
| FY 2023 | $566.8M | $34.12B | — | 79.3% | $274.7M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
COLL // BETA —
LLY // BETA 0.51